Kornimate/medical-research-clean huggingface dataset:
microbiome in lung cancer and other malignancies

Conditions: Lung Cancer; Cancer; Malignancy

Summary: to characterize the fecal, skin, nasal and oral microbiome and metabolome in patients with lung cancer and other malignancies, and correlate to treatment response and toxicities of various therapies including immunotherapy, chemotherapy and targeted therapy, etc.

patients will be asked to provide nasal, oral and skin swabs, as well as stool samples during their regular clinic visits, at the baseline before desired therapy is given, and at the time when treatment is changed due to either disease progression or unbearable toxicities leading to treatment stop/change. if treatment stop/held is due to toxicities, a 3rd set of samples will be collected when toxicities reduce to less than grade 1. the samples will be subjected to dna extraction followed by 16s rrna and/or shotgun sequencing metagenomic analysis. the data will be correlated to clinical response from treatments, toxicities, clinical data (use of antibiotics, ppis, lab parameters, etc.) and tissue genetic/immunological characteristics (mutations, pdl1 expression, etc.) for review of response. this is not data to be used for treatment of these subjects.

Eligibility criteria:
inclusion criteria: patients diagnosed with lung cancer and other malignancies who are candidates for systemic therapies such as immunotherapy and chemotherapy eligibility criteria for studying microbiome in patients receiving immunotherapy: * patients with advanced/recurrent lung cancer (including both nsclc and sclc) and other solid tumors of our study interest (e.g. gu cancer and melanoma, etc.) that initiate a new line of immunotherapy (can be 1st or later line), either alone or in combination with chemotherapy, targeted therapy or other immunotherapy. * patients can be in other clinical trials as long as they meet criteria 1. * prior treatment with immunotherapy is acceptable as long as criteria 1 is met. for example, a new line therapy with pembrolizumab plus pemetrexed after failing pembrolizumab is considered eligible. * patients who are to start immunotherapy maintenance after chemoradiation therapy are eligible (e.g. nsclc patients who will be on durvalumab maintenance) * patients who are to start immunotherapy after local therapies (e.g. radiation, ablation, etc.) are eligible. * immunotherapy must have component of anti-pd-1/pd-l1 agents (e.g. nivolumab, pembrolizumab, atezolizumab, durvalumab and avelumab, etc.) or anti-ctla4 (e.g. ipilimumab) exclusion criteria: * patients \< 18 years of age * patients that are pregnant * patients taking more than 2 alcoholic drinks per day and those using non-medical drugs such as marijuana, cocaine, heroine, etc.
a study of the enseal® x1 curved jaw tissue sealer and generator g11 in thoracic, urologic, and ear, nose, and throat (ent) procedures

Conditions: Thoracic Procedure; Urologic Procedure; Ear, Nose and Throat Procedure

Summary: the purpose of this study is to demonstrate the acceptable performance and safety of the enseal x1 curved jaw tissue sealer and ethicon endo-surgery generator g11 (gen11) devices when used per the instructions for use (ifu).


Eligibility criteria:
inclusion criteria: 1. primary laparoscopic or open procedure (thoracic, urologic or ear, nose, and throat \[ent\]) where at least one vessel is planned to be transected by the enseal x1 curved jaw tissue sealer (enseal x1) device per the instructions for use (ifu) 2. willingness to give consent and comply with all study-related evaluations and treatment schedule 3. at least 18 years of age exclusion criteria: 1. physical or psychological condition which would impair study participation 2. enrollment in a concurrent interventional clinical study that could impact the study endpoints
the efficacy and safety of a combination therapy of rosuvastatin and ezetimibe versus monotherapy of rosuvastatin in hypercholesterolemia patients

Conditions: Hypercholesterolemia

Summary: to evaluate efficacy and safety of a combination therapy of rosuvastatin and ezetimibe versus monotherapy of rosuvastatin in hypercholesterolemia patients

to evaluate efficacy and safety of a combination therapy of rosuvastatin and ezetimibe versus monotherapy of rosuvastatin in hypercholesterolemia patients

Eligibility criteria:
inclusion criteria: * hypercholesterolemic patient exclusion criteria: * has history of hypersensitivity to hmg-coa reductase inhibitor and ezetimibe

Keywords: cholesterol
spect-ct for assessment of total knee arthroplasty in navigated and non-navigated total knee arthroplasty

Conditions: Osteoarthritis; X-rays; Effects

Summary: by the comparison of two operation methods navigated and non-navigated tkr with spect/ct we want to show wich method has the better outcome.

with spect/ct we want to controll the clinical outcome of patients who underwent a navigated or a non-navigated tkr.

Eligibility criteria:
inclusion criteria: * total knee prosthesis (primary) * \>18 years exclusion criteria: * pregnancy * lactating women * endocrine diseases * tumour diseases * posttraumatic osteoarthritis of the knee * previous infection of the knee * medicaments which influence the metabolism of the bone

Keywords: total knee arthroplasty total knee prothesis spectrometry, x-ray emission spect/ct measurement of tka component position
immunogenicity and safety of booster dose of poliorixtm vaccine in previously vaccinated toddlers

Conditions: Poliomyelitis

Summary: this study aims to evaluate the persistence of anti-poliovirus antibodies in toddlers aged 18 months who were primed with oral polio vaccine (opv) or inactivated polio vaccine (ipv) in the primary study. the study will also assess the immunogenicity and reactogenicity of a booster dose of ipv in subjects primed with three doses of ipv.

all subjects will also receive a booster dose of gsk biologicals' dtpa/hib vaccine (infanrix+hib) at day 0. this vaccine will be provided as part of the local standard of care and will not be associated with any study endpoint.

Eligibility criteria:
inclusion criteria: * subjects who the investigator believes that their parent(s)/legally acceptable representative(s) can and will comply with the requirements of the protocol. * subjects who received the complete three-dose primary vaccination course in study nct01021293. * healthy male or female toddlers 18 to 24 months of age at the time of visit 1 (day 0). * written informed consent obtained from the parent(s)/ legally acceptable representative(s) of the subject. * healthy subjects as established by medical history and clinical examination before entering into the study. exclusion criteria: * child in care. * use of any investigational or non-registered product other than the study vaccine(s) within 30 days preceding the booster dose of study vaccine(s), or planned use during the study period. * chronic administration of immunosuppressants or other immune-modifying drugs within six months prior to visit 1 (day 0). * administration of immunoglobulins and/or any blood products within the 3 months preceding visit 1 (day 0) or planned administration during the study period. * administration of a vaccine not foreseen by the study protocol within 30 days of visit 1 (day 0) or planned administration during the study period. * concurrently participating in another clinical study, at any time during the study period, in which the subject has been or will be exposed to an investigational or a non-investigational product. * evidence of previous booster vaccination against poliomyelitis or the disease since the conclusion visit of study nct01021293. * history of seizures or progressive neurological disease. * any confirmed or suspected immunosuppressive or immunodeficient condition, based on medical history and physical examination. * history of any reaction or hypersensitivity likely to be exacerbated by any component of the vaccine. * major congenital defects or serious chronic illness. * acute disease and/or fever at the time of enrolment.

Keywords: ipv poliorixtm china
efficacy of g-csf-priming in elderly aml patients

Conditions: Acute Myeloid Leukemia

Summary: aim of the study is to compare the efficacy of intensive induction therapy with cytarabine, idarubicin and etoposide (idav) given in parallel with (g-csf priming) and followed by g-csf versus the same idav chemotherapy only followed by g-csf (without priming) in elderly patients with de novo aml, secondary aml and advanced mds. moreover, the ability to mobilize sufficient numbers of peripheral blood stem cells (pbsc) for autologous pbsc transplantation after consolidation therapy with dose-reduced flag-ida chemotherapy followed by g-csf will be evaluated.


Eligibility criteria:
inclusion criteria: * diagnosis of de-novo aml, fab m0, 1, 2, 4-7 or * diagnosis of secondary aml after previous chemotherapy and/or radiation therapy or after preceeding mds or * diagnosis of an advanced mds, i.e. raeb-t according to the fab classification or * extramedullary aml (chloroma, "granulocytic sarcoma") * age greater than 60 years (not including 60 years) * ecog performance status 0, 1, or 2 * written informed consent exclusion criteria: * patients with a t(15;17) translocation * patients with severe cardiac disease (e.g. cardiac failure nyha iii/iv, myocardial infarction within the last 6 months; severe ventricular arrythmias (lown iii or iv) * patients with severe complications of the leukemia such as uncontrolled bleeding, pneumonia with hypoxia or shock. * severe pulmonary disease (diffusion capacity for co2 of less than 50%) * significant renal dysfunction (creatinine clearance \< 60/min/min) * bilirubin \> 2mg% (\>34.2 mmol/l) * patients with a clinically active second malignancy * patients with a psychiatric, addictive, or any disorder wich compromises ability to give truly informed consent for participating in this study * hiv positivity * known refractoriness to platelet transfusion, inability to adequately substitute blood products
post-marketing surveillance (use result surveillance) with refixia®

Conditions: Haemophilia B

Summary: the participants are invited to take part in this study because they have haemophilia b. the purpose of this study is to assess the safety and effectiveness of refixia® about long-term routine use in patients with haemophilia b. the participants will get refixia® as prescribed to them by their study doctor. the study will last up to sep 2025 for the participant. the participants may be asked to fill in the quality of life questionnaires (if they are above age of 15). the blood samples taken from the participants as part of routine clinical practice will also be used to investigate the safety for the long-term use of refixia®.


Eligibility criteria:
inclusion criteria: * signed consent obtained before any study-related activities (study-related activities are any procedure related to recording of data according to the protocol). * the decision to initiate treatment with commercially available refixia® has been made by the patient/legally acceptable representative (lar) and the treating physician before and independently from the decision to include the patient in this study. at each site of this study, all patients will be registered consecutively from the first patient after the launch of refixia® (consecutively registered system). * diagnosis of haemophilia b in males or females, no age limitation. patients younger than 12 years old will continue to be registered for 3 years of recruitment period regardless of the target number of patients. * new patients who have not been previously exposed to refixia®. also patients previously exposed to refixia® in nn7999-3639, -3747, -3774, -3775 or -3895 clinical trial can be enrolled in this study. the patients who have participated in nn7999 -3774 or -3895 clinical trial can be enrolled in this study as continuous cases until 30-september-2024 (one year before planned end of study date). exclusion criteria: * previous participation in this study. participation is defined as having given informed consent in this study * mental incapacity, unwillingness or language barriers precluding adequate understanding or cooperation * known or suspected hypersensitivity to study product or related products.
the effect of rifaximin on portal vein thrombosis

Conditions: Cirrhosis; Portal Vein Thrombosis

Summary: the aim of this study is to evaluate the efficacy of rifaximin in the treatment of portal vein thrombosis in cirrhotic patients

portal vein thrombosis is not an uncommon complication in cirrhotic portal hypertension, which lead to a poor prognosis in endoscopic management of variceal bleeding. evidence indicated that enoxaparin prevented pvt and liver decompensation via decreased rates of bacterial infections and lowered the potent inflammatory mediators such as interleukin-6. rifaximin is a broad-spectrum antibiotic that exerts endotoxin-lowering and anti-inflammatory effects.

Eligibility criteria:
inclusion criteria: * 18 y.o. ≤age≤75 y.o * cirrhotic patients had cta confirmed portal vein trombosis * d-dimer no more than five times the normal upper limit exclusion criteria: * age \ 75 y.o. * had portal cavernoma * received anticoagulation treatment in the past 6 months * splenectomy * known infection after endoscopic treatment (fever, microbial cultures positive, et al.) * massive ascites or combined with other high risk factor that require prophylaxis use of antibiotics. * acute variceal bleeding within 5 days. * use of other antibiotics in the past 2 weeks * acute portal vein thrombosis
middle school parent module for a brief bullying intervention program

Conditions: Bullying

Summary: this study evaluates the feasibility and short-term outcomes of a parent training designed as a companion module to a bullying bystander intervention (stac) for middle school students in rural communities. the aim of this project is to provide a brief, low-cost intervention that can be easily disseminated as part of a school-based bullying prevention program to address this important public health problem.


Eligibility criteria:
inclusion criteria: 1. being a parent of an adolescent enrolled in grades 6, 7, or 8 in a participating middle school in idaho. 2. speaks and reads english. 3. consents to participate. exclusion criteria: 1. speaks and reads only a language other than english. 2. does not consent for participation.
anesthesia and perioperative neurocognitive disorders in the elderly patients undergoing hip fracture surgery platform trial (andes platform trial)

Conditions: Anesthesia; Hip Fractures; Dementia; Cognitive Impairment; Cognitive Decline

Summary: anesthesia and perioperative neurocognitive disorders in the elderly patients undergoing hip fracture surgery platform trial (andes platform trial): a pragmatic multi-arm, adaptive, open label, multicenter randomized controlled platform trial to assess the effect of different enhance anesthesia technique in perioperative neurocognitive function, as compared to standard anesthesia care in the elderly patients undergoing hip fracture


Eligibility criteria:
inclusion criteria: 1. aged 65 years and older. 2. patients with unilateral hip fracture (including femoral neck, femoral head, intertrochanteric and subtrochanteric fractures) are scheduled for surgical treatment. 3. american society of anesthesiologists (asa) physical status iv or below. 4. the patients or family members provide written informed consent. 5. additional inclusion criteria may pertain to specific interventions and will be described in relevant sub-protocols. exclusion criteria: 1. patients with multiple trauma or fractures (excluding trauma that the researcher judges will not affect the patient's overall recovery, such as simple spinal compression fractures, mild soft tissue contusions, fractures of hands and feet, etc.); 2. two or more anesthetic surgeries are required. 3. petients with an obvious history of head trauma (such as loss of consciousness for more than 5 minutes, post-traumatic amnesia, etc.); 4. patients who the researcher believes are unable to complete the assessment of primary outcome; 5. additional exclusion criteria may pertain to specific interventions and will be described in relevant sub-protocols.
extra corporeal shock wave versus kinesio tape in carpal tunnel syndrome

Conditions: Carpal Tunnel Syndrome

Summary: this study would be conducted to answer the following question: was there any difference between the effects of shock wave versus kinesio tape in the treatment of carpal tunnel syndrome for post-menopausal women.

fifty menopausal women with mild to moderate cts were selected randomly from outpatient clinic of the physical therapy department of el khazendara general hospital, age was ranged from 45 - 55 years old. group a, consisted of 25 patients who received a program of 6 session of shock wave therapy on the affected wrist,5 minute per session. group b represented the control group, it consisted of 25 patients who received a program of kinesio tape application on the affected wrist for 3 days.

Eligibility criteria:
inclusion criteria: * -age was ranged from 45 - 55 years old * all subjects would not take analgesics by another route during the study. exclusion criteria: * patients had previous carpal tunnel release. * skin over sensitivity of some patients to the tape.

Keywords: shock wave kinesio tape carpal tunnel syndrome
research study investigating how well nnc0174-0833 works in people suffering from overweight or obesity.

Conditions: Overweight; Obesity

Summary: this study will look at the change in body weight in people taking nnc0174-0833, liraglutide and "dummy" medicine, from the start to the end of the study. as well as taking the medicine, participants will have talks with study staff about healthy food choices, how to be more physically active and what participants can do to lose weight. participants will either take nnc0174-0833, liraglutide or "dummy" medicine - which treatment participants get is decided by chance. participants will need to take one injection once a week or once a day, depending on the treatment. the study medicine is injected with a thin needle in a skin fold in the stomach, thigh or upper arm. the study will last for about 8 months. participants will have 12 clinic visits with the study doctor.


Eligibility criteria:
inclusion criteria: * 18 years or older at the time of signing the informed consent. * female subject of non-childbearing potential or male subject who is surgically sterilised (vasectomy) or who is willing to use adequate contraceptive methods (as required by local regulation or practice) throughout the trial (until 'end of trial'). * bmi equal to 30.0 kg/m\^2 or greater or bmi equal to 27.0 kg/m\^2 or greater with the presence of at least one of the following weight-related comorbidities (treated or untreated): hypertension or dyslipidaemia (to be assessed at the investigator's discretion). exclusion criteria: * hba1c equal to 48 mmol/mol (6.5 percentage) or greater as measured by the central laboratory at screening. * a self-reported change in body weight greater than 5 kg (11 lbs) within 90 days prior to screening irrespective of medical records.
stimulation of the efferent loop before loop ileostomy closure

Conditions: Ileostomy - Stoma; Ileostomy; Complications; Stoma Ileostomy; Ileus Paralytic

Summary: the purpose of the study is to determine the impact of the efferent loop stimulation of a loop ileostomy prior to closure on postoperative complications such as ileus and hospital stay

stimulation was performed 3 weeks prior to the ileostomy closure using 500 cc of a thickening substance (saline and nutritional thickener) through the efferent limb.

Eligibility criteria:
inclusion criteria: * patients with loop ileostomy * barium transit throught the efferent limb without leaks exclusion criteria: * chemotherapy at the moment * ileostomy closure at the same admission than the ileostomy creation
the effect of oculomotor exercises in the warm-up on forehand and backhand stroke performance in tennis players

Conditions: Supportive Care

Summary: 30 tennis players aged 12-18, will be included in the study. after their normal warm-up, the participants will make 30 forehand and 30 backhand strokes. forehand and backhand stroke accuracy rate will be calculated. after a week, additional oculo-motor exercises will be included in the warm-up and the forehand and backhand stroke accuracy rate will be calculated again. the hypothesis that there will be an improvement in forehand and backhand stroke accuracy after oculo-motor exercises will be tested.

30 tennis players aged 12-18, who practice tennis for at least 6 hours a week and have been playing regularly for at least 1 year will be included in the study. the positive effect of oculo-motor exercises to be included in the pre-tennis warm-up program on stroke performance will be investigated. as oculo-motor exercises, 3 different exercises will be applied: stepping exercise with eye movements and head rotation (the eyes are fixed on the thumb and the head rotates right and left and walks 10 steps forward and 10 steps back.), accommodation (first eyes fixed on the near target, then fixed on a target approximately 20-30 m away.) and pen tracking with 5 different movements (horizontal, vertical, diagonal, circular, infinite eight). participants will be given a backhand and forehand stroke evaluation consisting of a total of 60 strokes, 30 forehand and 30 backhand. in the first evaluation, the participants will be asked to do their regular warm-up program. the area between the baseline line, service line and singles side line on the tennis court will be marked and two target areas will be created, one on the right and one on the left. players will be asked to take one stroke parallel and one stroke diagonally, and they will be expected to hit the marked target areas. one week later there will be a second evaluation. in the second evaluation, oculo-motor exercises will be included in the participants' warm-up programs and the stroke evaluation will be repeated. the data obtained will be evaluated whether oculo-motor exercises have a positive effect on the forehand and backhand stroke rate.

Eligibility criteria:
inclusion criteria: * being 12-18 years old * playing tennis for at least 6 hours a week * having been playing tennis for at least 1 year * no visual defect (myopia, hyperopia, astigmatism) exclusion criteria: * being under 12 years old * being over 18 years old * playing tennis for less than 6 hours a week * the duration of playing tennis is less than 1 year * having visual impairment (myopia, hyperopia, astigmatism)

Keywords: tennis oculomotor exercise